Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Ascendis Pharma A/S - Ordinary Share
(NQ:
ASND
)
250.51
+1.53 (+0.62%)
Delayed Quote
Updated: 11:13 AM EST, Nov 3, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ascendis Pharma A/S - Ordinary Share
< Previous
1
2
3
4
5
6
7
8
9
Next >
What 9 Analyst Ratings Have To Say About Ascendis Pharma
↗
November 29, 2022
Via
Benzinga
Analyst Ratings for Ascendis Pharma
↗
November 29, 2022
Via
Benzinga
Why Infinity Pharmaceuticals Shares Tumbled Around 38%; Here Are 79 Biggest Movers From Yesterday
↗
November 15, 2022
Gainers Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) shares surged 113.8% to settle at $20.10 on Monday. Indivior PLC agreed to acquire Opiant Pharmaceuticals for $20.00 per share in cash, plus...
Via
Benzinga
Ascendis Pharma's Program Hits Primary Goal In Children With Short-Limbed Dwarfism
↗
November 14, 2022
Via
Benzinga
Analyst Ratings for Ascendis Pharma
↗
November 07, 2022
Ascendis Pharma (NASDAQ:ASND) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Why Opiant Pharmaceuticals Shares Are Trading Higher By 115%? Here Are 53 Stocks Moving In Monday's Mid-Day Session
↗
November 14, 2022
Gainers Freight Technologies, Inc. (NASDAQ: FRGT) shares surged 137% to $0.4901 after analysts at Chardan Capital initiated coverage of the stock with a $2.25 price target.
Via
Benzinga
Hasbro, Ascendis Pharma, Coinbase Global And Some Other Big Stocks Moving Lower On Monday
↗
November 14, 2022
U.S. stocks traded mixed, with the Nasdaq gaining more than 50 points on Monday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
6 Analysts Have This to Say About Ascendis Pharma
↗
October 20, 2022
Ascendis Pharma (NASDAQ:ASND) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Expert Ratings for Ascendis Pharma
↗
September 22, 2022
Within the last quarter, Ascendis Pharma (NASDAQ:ASND) has observed the following analyst ratings:
Via
Benzinga
Expert Ratings for Ascendis Pharma
↗
August 30, 2022
Analysts have provided the following ratings for Ascendis Pharma (NASDAQ:ASND) within the last quarter:
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
November 14, 2022
Gainers Opiant Pharma (NASDAQ:OPNT) stock rose 118.3% to $20.74 during Monday's pre-market session. The market value of their outstanding shares is at $107.1 million. As per the press release, Q3...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 20, 2022
↗
October 20, 2022
Upgrades
Via
Benzinga
Ascendis Seeks FDA Nod For TransCon PTH In Adults With Hypoparathyroidism
↗
August 31, 2022
Ascendis Pharma (NASDAQ: ASND) has submitted a New Drug Application (NDA) to the U.S. Food & Drug Administration (FDA) for TransCon PTH, an investigational pro-drug designed to restore parathyroid...
Via
Benzinga
What 14 Analyst Ratings Have To Say About Ascendis Pharma
↗
May 12, 2022
Within the last quarter, Ascendis Pharma (NASDAQ:ASND) has observed the following analyst ratings:
Via
Benzinga
Where Ascendis Pharma Stands With Analysts
↗
January 27, 2022
Over the past 3 months, 4 analysts have published their opinion on Ascendis Pharma (NASDAQ:ASND) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...
Via
Benzinga
Oppenheimer Maintains Outperform Rating for Ascendis Pharma: Here's What You Need To Know
↗
August 11, 2022
Oppenheimer has decided to maintain its Outperform rating of Ascendis Pharma (NASDAQ:ASND) and lower its price target from $154.00 to $144.00. Shares of Ascendis Pharma are trading up 8.7% over the...
Via
Benzinga
Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial
↗
August 10, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Ascendis Slammed After Growth Hormone Drug Faces An Unexpected Challenge
↗
May 12, 2022
Ascendis Pharma sells a treatment for children with insufficient growth hormone.
Via
Investor's Business Daily
The Daily Biotech Pulse: Novartis Prostate Cancer Drug Lands FDA Approval, Ligand Announces SPAC Deal To Spin Off Antibody Business, Lilly's Lung Cancer Therapy Hit With CRL
↗
March 24, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
BofA Upgrades Ascendis Pharma After Promising TCP Phase 3 Data
↗
March 15, 2022
Following Ascendis Pharma’s (NASDAQ: ASND) reporting of positive topline Phase III data for its PaTHway trial of TransCon PTH (TCP) in adults with hypoparathyroidism, the...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 15, 2022
↗
March 15, 2022
Upgrades For Turquoise Hill Resources Ltd (NYSE:TRQ), BMO Capital upgraded the previous rating of Underperform to Market Perform. Turquoise Hill Resources earned $0.78 in the...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
March 14, 2022
Gainers Erytech Pharma (NASDAQ:ERYP) stock rose 18.7% to $1.65 during Monday's pre-market session. The market value of their outstanding shares is at $51.1 million....
Via
Benzinga
10 Biggest Price Target Changes For Monday
↗
March 14, 2022
Wells Fargo raised the price target on Laredo Petroleum, Inc. (NYSE: LPI) from $72 to $113. Laredo Petroleum shares fell 2.8% to $71.00 in pre-market trading.
Via
Benzinga
Ascendis Pharma's Hypoparathyroidism Trial Meets Primary, Secondary Endpoints
↗
March 14, 2022
Ascendis Pharma A/S (NASDAQ: ASND) announced topline data from its Phase 3 PaTHway Trial of TransCon PTH in adults with hypoparathyroidism (HP), a condition in...
Via
Benzinga
7 Biotech Stocks With Key Catalysts in March
↗
March 09, 2022
These seven stocks have some key catalysts lined up for March with the potential to move their price actions in big ways.
Via
InvestorPlace
Expert Ratings For Ascendis Pharma
↗
March 07, 2022
Within the last quarter, Ascendis Pharma (NASDAQ:ASND) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total...
Via
Benzinga
The Daily Biotech Pulse: NuCana Shelves Biliary Tract Cancer Study, Tricida Data Readout Pushed Back Due to Ukrainian Crisis, Synlogic Names New CFO
↗
March 03, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus NuCana Discontinues Biliary Tract Cancer Study Following Futility Analysis...
Via
Benzinga
Earnings Scheduled For March 2, 2022
↗
March 02, 2022
Companies Reporting Before The Bell • SIGNA Sports United (NYSE:SSU) is expected to report quarterly loss at $0.04 per share on revenue of $283.61 million. •...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2022
↗
March 01, 2022
Upgrades Stifel upgraded the previous rating for Revolution Medicines Inc (NASDAQ:RVMD) from Hold to Buy. For the fourth quarter, Revolution Medicines had an EPS of $0.71,...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 14, 2022
↗
February 14, 2022
Upgrades According to Mizuho, the prior rating for Murphy Oil Corp (NYSE:MUR) was changed from Neutral to Buy. In the fourth quarter, Murphy Oil showed an EPS of $0.40,...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
